Scheid DC, Hamm RM. Acute bacterial rhinosinusitis in adults: part II. Treatment. Am Fam Physician, 2004, 70: 1697-704, 1711-2.
Gwaltney JMJr. Acute community-acquired sinusitis. Clin Infect Dis, 1996, 23: 1209-23.
Dosh SA, Hickner JM, Mainous A G3d, Ebell MH. Predictors ofantibiotic prescribing for nonspecific upper respirator у infections, acute bronchitis, and acute sinusitis. An UPRNet study. Upper Peninsula Research Network. J Fam Pract, 2000, 49: 407-14.
Ueda D, Yoto Y. The ten-day mark as a practical diagnostic approach for acute paranasal sinusitis in children. Pediat Infect Dis J, 1996, 15: 576-9.
Diagnosis and treatment of acute bacterial rhinosinusitis. Evid Rep Technol Assess (Summ), 1999, 9: 1-5.
Hickner JM, Bartlett JG, Besser RE, Gonzales R, Hoffman JR, Sande MA. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med, 2001, 134: 498-505.
Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother., 2003, 52(2): 229-246.
Brunton S. Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin. Ther., 2006, 28(1): 118-123.
Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis., 2004, 23(9): 829-833.
Low DE, Desrosiers M, McSherry J, Garber G, Williams JWJr, Remy H, et al. A practical guide for the diagnosis and treatment of acute sinusitis. CMAJ, 1997, 156(Suppl 6): 1-14.
Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis., 2007, 26(2): 123-128.
Jansen WTM, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenza. J Antimicro. Chemother., 2006, 58: 873-877.
Hausen Th, Weidlich G, Schmitt J. Safety and efficacy of cefixime in the treatment of respiratory tract infections in Germany. Infection, 1995, 23(suppl 2): 65–69.
McLinn SE. Randomized, open label, multicenter trial of cefixime compared with amoxicillin for treatment of acute otitis media with effusion. Pediatr Infect Dis J, 1987, 6: 997–1001.
Owen MJ, Anwar R, Nguyen HK, Swank PR, Bannister ER, Howie VM: Efficacy of efixime in the treatment of acute otitis media in children. Am J Dis Child, 1993, 147: 81–86.
Johnson CE, Carlin SA, Super DM, Rehmus JM, Roberts DG, Christopher NC, Whitwell JK, Shurin PA. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr, 1991, 119: 117–122.
Rodriguez WJ, Khan W, Sait T,Chhabra OP, Bell TA, Akram S, Kohlbrenner VM: Cefixime vs. cefaclor in the treatment of acute otitis media in children: A randomized, comparative study. Pediatr Infect Dis J, 1993, 12: 70–74.
Gooch WM III, Philips A, Rhoades R, Rosenberg R, Schaten R, Starobin S: Comparison of the efficacy,safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J, 1997, 16(suppl 2): 21–24.
Яковлев С.В. Стратегия и тактика рационального применения антибиотиков. Consilium medicum, Экстравыпуск, 2013: 3-4
Фомина И.П., Смирнова Л.Б. Современное значение орального цефалоспорина III поколения цефиксима в терапии бактериальных инфекций. Инфекции и антимикробная терапия, 2012, 4(3): 38–40.
Brogden RN, Campoli Richards DM. Cefixime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs, 1989, 38: 524–50.